Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.
Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.
复制标题
DOI：
10.1186/s13195-023-01245-2
复制
发表时间：
2023-06-03
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
目前对可能的脑淀粉样血管病(CAA)的诊断大多基于脑MRI的特征。血液生物标记物将是一种成本效益高、易于获得的诊断方法，可以补充MRI的诊断，并有助于监测疾病进展。我们研究了血浆A-β38、A-β40和A-β42对遗传性荷兰型再生障碍性贫血和散发性再生障碍性再生障碍性贫血的诊断价值。在发现队列(11例有症状前和24例有症状的患者，分别为16例和24例匹配的对照组)和一个独立的验证队列(54例有症状的患者，26例有症状的患者和28例有症状的患者，39例和46例匹配的对照组)中，所有的A-β多肽都通过免疫分析方法在血浆中定量。此外，对61例SCAA患者和42例匹配的对照组的血浆中的多肽进行了定量。我们通过对年龄和性别进行线性回归调整，比较了患者和对照组之间的Aβ多肽水平。在发现的队列中，我们发现，与对照组相比，无症状的慢性再生障碍性贫血患者(Aβ38：P <； 0.001；Aβ40：P = 0.009；Aβ42：P <； 0.001)和有症状的D-CAA患者(Aβ38：P <； 0.001；Aβ40：P = 0.01；Aβ42：P <； 0.001)的所有Aβ肽水平显著降低。相反，在验证队列中，无症状的慢性再生障碍性贫血患者和对照组的血浆Aβ38、Aβ40和Aβ42相似(Aβ38：P = 0.18；Aβ40：P = 0.28；Aβ42：P = 0.63)。有症状组和对照组血浆Aβ38和Aβ40相似(Aβ38：P = 0.14；Aβ40：P = 0.38)，而Aβ42在有症状性D-CAA组显著降低(p = 0.033)。慢性再生障碍性贫血患者和对照组的血浆Aβ38、Aβ40和Aβ42水平相似(Aβ38：P = 0.092；Aβ40：P = 0.64.Aβ42：P = 0.68)。血浆A-β42水平，而不是A-β38和A-β40水平可作为有症状的D-CAA患者的生物标志物。相反，血浆Aβ38、Aβ40和Aβ42水平似乎不适合作为SCAA患者的生物标志物。
The diagnosis of probable cerebral amyloid angiopathy (CAA) is currently mostly based on characteristics of brain MRI. Blood biomarkers would be a cost-effective, easily accessible diagnostic method that may complement diagnosis by MRI and aid in monitoring disease progression. We studied the diagnostic potential of plasma Aβ38, Aβ40, and Aβ42 in patients with hereditary Dutch-type CAA (D-CAA) and sporadic CAA (sCAA). All Aβ peptides were quantified in the plasma by immunoassays in a discovery cohort (11 patients with presymptomatic D-CAA and 24 patients with symptomatic D-CAA, and 16 and 24 matched controls, respectively) and an independent validation cohort (54 patients with D-CAA, 26 presymptomatic and 28 symptomatic, and 39 and 46 matched controls, respectively). In addition, peptides were quantified in the plasma in a group of 61 patients with sCAA and 42 matched controls. We compared Aβ peptide levels between patients and controls using linear regression adjusting for age and sex. In the discovery cohort, we found significantly decreased levels of all Aβ peptides in patients with presymptomatic D-CAA (Aβ38: p < 0.001; Aβ40: p = 0.009; Aβ42: p < 0.001) and patients with symptomatic D-CAA (Aβ38: p < 0.001; Aβ40: p = 0.01; Aβ42: p < 0.001) compared with controls. In contrast, in the validation cohort, plasma Aβ38, Aβ40, and Aβ42 were similar in patients with presymptomatic D-CAA and controls (Aβ38: p = 0.18; Aβ40: p = 0.28; Aβ42: p = 0.63). In patients with symptomatic D-CAA and controls, plasma Aβ38 and Aβ40 were similar (Aβ38: p = 0.14; Aβ40: p = 0.38), whereas plasma Aβ42 was significantly decreased in patients with symptomatic D-CAA (p = 0.033). Plasma Aβ38, Aβ40, and Aβ42 levels were similar in patients with sCAA and controls (Aβ38: p = 0.092; Aβ40: p = 0.64. Aβ42: p = 0.68). Plasma Aβ42 levels, but not plasma Aβ38 and Aβ40, may be used as a biomarker for patients with symptomatic D-CAA. In contrast, plasma Aβ38, Aβ40, and Aβ42 levels do not appear to be applicable as a biomarker in patients with sCAA.
登录
查看更多内容
人血浆中的β-淀粉样动力学。
影响因子：
--
作者：
Huang Y;Potter R;Sigurdson W;Kasten T;Connors R;Morris JC;Benzinger T;Mintun M;Ashwood T;Ferm M;Budd SL;Bateman RJ
通讯作者：
Bateman RJ
影响因子：
29
作者：
Charidimou A;Martinez-Ramirez S;Reijmer YD;Oliveira-Filho J;Lauer A;Roongpiboonsopit D;Frosch M;Vashkevich A;Ayres A;Rosand J;Gurol ME;Greenberg SM;Viswanathan A
通讯作者：
Viswanathan A
DOI：
10.1016/j.jalz.2012.01.001
发表时间：
2012-07
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Figurski MJ;Waligórska T;Toledo J;Vanderstichele H;Korecka M;Lee VM;Trojanowski JQ;Shaw LM;Alzheimer’s Disease Neuroimaging Initiative
通讯作者：
Alzheimer’s Disease Neuroimaging Initiative
影响因子：
--
作者：
Bjerke, Maria;Portelius, Erik;Blennow, Kaj
通讯作者：
Blennow, Kaj
影响因子：
9.9
作者：
Doecke, James D.;Perez-Grijalba, Virginia;Sarasa, Manuel
通讯作者：
Sarasa, Manuel